[Somatostatin in a case of neonatal hyperinsulinism caused by focal adenomatosis of the head of pancreas].
The use of somatostatin in the treatment of a newborn infant with hyperinsulinism is reported. When administered alone, somatostatin was only able to prevent hypoglycemia for a short period of time, whereas the addition of a constant infusion of glucagon allowed successful control of the patient's hypoglycemia. As hyperinsulinism relapsed after a subtotal pancreatectomy, a trial was carried out with a somatostatin analog, which has an expected longer duration of action. It led to a significant rise in the blood glucose level but failed to prevent safely hypoglycemia even when 4 injections were performed daily.
D000236:Adenoma / Q000150:complications*; D004200:Diseases in Twins; D005260:Female; D006801:Humans; D006946:Hyperinsulinism / Q000151:congenital* / Q000209:etiology; D007003:Hypoglycemia / Q000209:etiology; D007231:Infant, Newborn; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000150:complications*; D012008:Recurrence; D013004:Somatostatin / Q000627:therapeutic use*
D013004:Somatostatin
La somatostatine dans un cas d'hyperinsulinisme néonatal par adénomatose focale de la tête du pancréas.